CommunityRx-Kidney Health
NCT07237295 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 634
Last updated 2026-04-30
Summary
In the United States, the burden of chronic kidney disease (CKD) rests disproportionately on rural communities. This study evaluates the implementation and effectiveness of CommunityRx-Kidney Health (CRx-K); this health information technology intervention integrates medical, social, and self-care resources to improve CKD management in rural eastern North Carolina. Through a partnership among local primary care centers, community organizations, and researchers, CRx-K will strengthen rural care networks, improve CKD management, and enhance the well-being of rural communities.
Conditions
- Chronic Kidney Disease (Stages 1-4)
Interventions
- BEHAVIORAL
-
CommunityRx-Kidney Health
CommunityRx-Kidney Health (CRx-K) is an evidence-based, low-intensity, health information technology-driven intervention designed to support chronic kidney disease management in rural eastern North Carolina. CRx-K integrates medical (e.g., blood pressure and glucose monitoring, eye and foot care), social (food, housing, transportation), and self-care (weight and stress management, exercise) resources. CRx-K comprises three components: brief education on integrated chronic kidney disease needs, a personalized community resource referral list (HealtheRx), and clinic navigator-led, longitudinal support (12 months) for chronic kidney disease patients.
Sponsors & Collaborators
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
collaborator NIH -
Goshen Medical Center
collaborator UNKNOWN -
James McFarlin Community Development, Inc.
collaborator OTHER - collaborator OTHER
-
Project GRACE
collaborator UNKNOWN -
Project Momentum, Inc.
collaborator INDUSTRY -
UniteUs
collaborator UNKNOWN -
University of Chicago
collaborator OTHER -
University of North Carolina, Chapel Hill
lead OTHER
Principal Investigators
-
Gaurav J Dave, MBBS, MPH, DrPH · University of North Carolina, Chapel Hill
-
Abhijit V Kshirsagar, MD, MPH · University of North Carolina, Chapel Hill
-
Stacy Tessler Lindau, MD, MA · University of Chicago
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-13
- Primary Completion
- 2028-06-30
- Completion
- 2028-06-30
Countries
- United States
Study Locations
More Related Trials
-
Safety Study of GCS-100 to Treat Chronic Kidney Disease
NCT01717248 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
NCT02837237 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis
NCT00750295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease
NCT01156428 ·Status: COMPLETED
-
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
NCT00843349 ·Status: COMPLETED ·Phase: NA
-
The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study
NCT04741386 ·Status: COMPLETED
-
Genetic Testing to Understand and Address Renal Disease Disparities
NCT02234063 ·Status: COMPLETED ·Phase: NA
-
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05521191 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
NCT05468749 ·Status: COMPLETED ·Phase: PHASE1
-
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
NCT01736397 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome
NCT03019653 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function
NCT01367509 ·Status: COMPLETED ·Phase: PHASE1
-
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
NCT03726307 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
NCT03832114 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
NCT00596518 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001
NCT03126318 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
NCT04527328 ·Status: COMPLETED ·Phase: NA
-
Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
NCT02738905 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
NCT04123613 ·Status: COMPLETED ·Phase: PHASE2
-
Tamsulosin and the Risk of Serious Adverse Events
NCT07274228 ·Status: COMPLETED
-
Evaluation of New Markers to Assess Kidney Function
NCT00938561 ·Status: WITHDRAWN
-
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 2 Extension Study of Study GCS-100-CS-4002
NCT02155673 ·Status: COMPLETED ·Phase: PHASE2
-
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT06794996 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
NCT03617536 ·Status: COMPLETED ·Phase: PHASE2